# Right ventricular dysfunction improves prediction of atrial fibrillation in hypertrophic cardiomyopathy: a cardiac magnetic resonance study

## TL;DR

Right ventricular dysfunction helps predict atrial fibrillation in patients with hypertrophic cardiomyopathy, improving risk assessment beyond traditional markers.

## Contribution

This study shows that right ventricular function adds new predictive value for atrial fibrillation in hypertrophic cardiomyopathy patients.

## Key findings

- RV dysfunction is common in HCM patients with AF and is linked to new-onset AF.
- RVEF and RV-PFR significantly improve AF risk prediction when added to clinical models.
- Age and left atrial diameter remain key predictors of new-onset AF in HCM.

## Abstract

Atrial fibrillation (AF) is a critical arrhythmia in hypertrophic cardiomyopathy (HCM), yet the role of right ventricular (RV) dysfunction in AF risk stratification remains underexplored. We aimed to evaluate the association between RV remodeling and incident AF in HCM patients.

This retrospective cohort study included 612 HCM patients who underwent cardiac magnetic resonance (CMR) at our institution (2016–2023). Incident AF was identified via electronic medical records or structured telephone interviews. RV function was assessed using CMR-derived parameters, including ejection fraction (RVEF), peak emptying rate (PER), and peak filling rate (PFR).

Among 612 patients (66.1% male), 72 (11.8%) had preexisting AF, and 29 (5.4%) developed new-onset AF over a median follow-up of 3.3 years. Patients with AF (preexisting or new-onset) exhibited older age and impaired RV function at baseline, including reduced RVEF, PER, and PFR (P < 0.05 for all). Multivariable Cox regression identified age, left atrial diameter (LAD), RVEF, and RV-PFR as independent predictors of new-onset AF. Adding RVEF and RV-PFR to a clinical model (age, NYHA class III/IV, LAD) significantly improved risk stratification (NRI: 0.80, P < 0.01; IDI: 0.07, P < 0.01).

RV dysfunction is prevalent in HCM patients with AF and provides incremental prognostic value for predicting new-onset AF beyond traditional clinical markers. These findings underscore RV functional assessment as a critical tool in AF risk stratification for HCM patients.